Janssen Research & Development announced the launch of three new clinical trials to evaluate rivaroxaban for the treatment of deep vein thrombosis and pulmonary embolism.
The new studies are part of the EXPLORER global CV research program for rivaroxaban (Xarelto), which is funded by Janssen and Bayer HealthCare. The program will include more than 11,000 patients in 30 countries, according to a press release.
Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.